Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Demand for Therapies to Treat Drug Resistant HIV Strains is Increasing Finds Frost & Sullivan - The HIV/AIDS market in Europe faces a number of hurdles in the form of late diagnosis and low awareness levels
Demand for Therapies to Treat Drug Resistant HIV Strains is Increasing Finds Frost & Sullivan

 

PRZOOM - /newswire/ - London, United Kingdom, 2009/09/28 - The HIV/AIDS market in Europe faces a number of hurdles in the form of late diagnosis and low awareness levels.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

However, the market is projected to exhibit strong growth due to the introduction of novel drug classes and increasing efforts to achieve high diagnosis rates.

New analysis from Frost & Sullivan (pharma.frost.com), European HIV/AIDS Therapeutics Markets, finds that the markets earned revenues of $3.88 billion in 2008 and estimates this to reach $6.79 billion in 2015.

"Market growth will be spurred by the new drug classes and combination therapies introduced recently," notes Sylvia M. Findlay, programme manager Pharmaceuticals & Biotechnology from Frost & Sullivan. "Novel drug classes which treat drug resistant HIV strains are expected to be used in combination with first-line therapy in experienced patients. Combination therapies which minimise side-effects and pill burden are supporting market development."

New drug classes are being researched and introduced into the market, especially targeting experienced patients. These drugs are being tested in clinical trials for use in combination with established first-line therapies and also as first-line therapies themselves. Proving the long-term safety and efficacy of these drugs is anticipated to boost their uptake and revenues.

Europe is already at a disadvantage because of the ban on direct-to-consumer marketing. Moreover, the launch and subsequent uptake of drugs is slower than in the US market. Social stigma and discrimination associated with HIV/AIDS, especially in Eastern Europe, is further limiting the growth potential of the market.

"Europe is a very diverse market where epidemiology, regulations and awareness levels vary considerably," explains Miss Findlay. "The level of adherence to recommended therapy regimens varies across the region, largely due to the lack of awareness about the safety and efficacy profiles of drugs used."

Moreover, diagnoses rates, which are influenced by awareness and societal pressures, vary across the region. This demands the formulation of region-specific strategies to promote market growth.

Companies need to update their knowledge of epidemiology, promote adherence to recommended therapies and enhance awareness on a continuous basis. They need to devise strategies to address challenges that impede the growth of their product portfolio. Market participants should use prescription trends to assess the market potential for their drugs, both as a first-line and a second-line therapy.

"Physicians are the sole point of contact for patients in Europe, given the absence of direct-to-consumer marketing," says Miss Findlay. "Analysing prescription trends and patients' perception towards new drugs as well as the drugs they are currently using is imperative to maintain patient base."

European HIV/AIDS Therapeutics Markets covers nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors, protease inhibitors and fusion inhibitors. The research service is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: European Therapeutic Monoclonal Antibody Markets, European Pharma/Biotech Contract Manufacturing Markets: A Strategic Outlook, European Human Growth Hormones Market and, European Drug Delivery Markets - Opportunity Analysis. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Katja Feick, Corporate Communications, at katja.feick[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by email.

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents.

European HIV/AIDS Therapeutics Markets / M335

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Demand for Therapies to Treat Drug Resistant HIV Strains is Increasing Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Katja Feick 
+49 (0) 69 7703343 katja.feick[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Triggr & Bloom

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today